Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | GRK5 | P34947 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226636 | 0.81 | MAPK14 (0.40) | MAPK14RAF1KDM4EALDH1A1 | |
| SCHEMBL10308265 | 0.78 | MAPK14 (0.50) | MAPK14RAF1KDM4EALDH1A1GAA | |
| SCHEMBL6918715 | 0.72 | MAPK14 (0.53) | MAPK14RAF1KDM4EKDRCDK8 | |
| SCHEMBL3226707 | 0.68 | MAPK14 (1.00) | MAPK14RAF1ALDH1A1MAPTATM | |
| SCHEMBL21590002 | 0.66 | ATAD2 (0.33) | — | |
| SCHEMBL24126358 | 0.65 | ATAD2 (0.32) | — | |
| SCHEMBL10978480 | 0.65 | KDM4E (0.53) | KDM4EABL1ALDH1A1GAAHSD17B10 | |
| SCHEMBL30437832 | 0.64 | KDM4E (0.57) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL20690360 | 0.64 | KDM4E (0.57) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL12851777 | 0.64 | MAPK14 (0.38) | MAPK14RAF1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| EP-0986382-B1 | RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20050256174-A1 | Raf kinase inhibitors | BAYER HEALTHCARE LLC | 2005-11-17 | — | — | US | disclosed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | MAPK14 40/4885RAF1 237/4885KDM4E 2456/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 40/4885RAF1 237/4885KDM4E 2456/4885 |
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885KDM4E 2074/4885 |
| US-20050256174-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885KDM4E 2074/4885 |
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885KDM4E 2074/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885KDM4E 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.